Physician profile
Nabil S Kamel
NPI 1326080276
$1,970.50
in general payments reported to CMS, 2019-2025
19 companies · $915 in 2025
The $915 reported for 2025 was more than what 88% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $454 · 2024: $602 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.39 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $374.32 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Eisai INC. | $261.94 | 2025 | |
| Neurocrine Biosciences, INC. | $227.45 | 2023-2024 | Ingrezza |
| Abbott Laboratories | $218.85 | 2023-2025 | Freestyle Libre |
| Novo Nordisk INC | $151.31 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $142.04 | 2025 | Kisunla, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $120.24 | 2023-2025 | Rexulti |
| Mylan Specialty L.P. | $72.43 | 2023-2024 | Yupelri |
| Pfizer INC. | $69.63 | 2024-2025 | |
| Dexcom, INC. | $65.86 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $61.60 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.20 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $40.06 | 2024-2025 | Belbuca |
| Amgen INC. | $27.57 | 2023-2025 | Repatha, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $22.99 | 2024 | Gemtesa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.96 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.49 | 2025 | Xifaxan |
| Viatris Specialty LLC | $16.45 | 2025 | Yupelri |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.